Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02AVL
|
|||
Drug Name |
ZK-813039
|
|||
Synonyms |
DE-00684; Factor Xa inhibitor (oral), Schering AG/Pfizer
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C23H19Cl3N6O3S
|
|||
Canonical SMILES |
CNC1=NC=CN1CC2=CSC(=C2Cl)C(=O)NC3=C(C=C(C=C3OC)Cl)C(=O)NC4=NC=C(C=C4)Cl
|
|||
InChI |
1S/C23H19Cl3N6O3S/c1-27-23-28-5-6-32(23)10-12-11-36-20(18(12)26)22(34)31-19-15(7-14(25)8-16(19)35-2)21(33)30-17-4-3-13(24)9-29-17/h3-9,11H,10H2,1-2H3,(H,27,28)(H,31,34)(H,29,30,33)
|
|||
InChIKey |
LLHSZBPXQIOQJJ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 229336-92-9
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Coagulation factor Xa (F10) | Target Info | Modulator | [1] |
KEGG Pathway | Complement and coagulation cascades | |||
Panther Pathway | Blood coagulation | |||
Pathwhiz Pathway | Coagulation | |||
Pathway Interaction Database | Beta2 integrin cell surface interactions | |||
Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
Intrinsic Pathway of Fibrin Clot Formation | ||||
Common Pathway of Fibrin Clot Formation | ||||
Gamma-carboxylation of protein precursors | ||||
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | ||||
Removal of aminoterminal propeptides from gamma-carboxylated proteins | ||||
WikiPathways | Complement and Coagulation Cascades | |||
Human Complement System | ||||
PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | ||||
Blood Clotting Cascade | ||||
Formation of Fibrin Clot (Clotting Cascade) |
References | Top | |||
---|---|---|---|---|
REF 1 | Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.